WFAE’s Claire Donnelly filed this Nov. 2 report about a new COVID-19 vaccine trial in which Tryon Medical Partners is participating, along with four other sites in North Carolina.
The ENSEMBLE Study will evaluate the safety and efficacy of investigational COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S, created by Janssen Pharmaceutical Companies of Johnson & Johnson.
Those interested in participating in the trial should call Tryon Medical Partners’ dedicated line at 704-586-9386. Prospective participants are encouraged to leave a message.
Here are the details of the WFAE story; please visit WFAE.org to read the story in its entirety.
- Five North Carolina locations are joining a Phase 3 trial for a COVID-19 vaccine developed by the company Johnson & Johnson, including Charlotte’s Tryon Medical Partners.
- Tryon Medical Partners, which has about 145,000 patients, said it plans to enroll up to 900 participants beginning this week.
- Participants in the trial will receive a single shot — either the experimental vaccine or the placebo — and will be monitored for two years.
- Participants do not need to live in Charlotte or be existing patients at the practice.
- Johnson & Johnson recently announced that it would resume recruiting people for its Janssen COVID-19 vaccine trial. The company previously paused all clinical trials of its experimental vaccine after a study participant became sick with “an unexplained illness,” according to a statement it issued Oct. 12. According to the company, “no clear cause has been identified” for the study participant’s illness.
- Tryon began participating in a separate COVID-19 vaccine trial in July. The practice enrolled about 460 people in the Phase 3 trial of a vaccine manufactured by the company Moderna, according to a Tryon spokesperson. It is one of about 90 locations across the U.S. involved in that trial.